Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK-C-0701 vs Alpha-Lipoic Acid in Diabetic Neuropathy
NCT01261143Phase 3Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- Aug 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of (R)-alpha lipoic acid in diabetic neuropathy (2 arms), sponsored by Bukwang Pharmaceutical. Primary endpoint: Total Symptom Score at 8 weeks. Started Aug 2010; status: completed.
02
Drugs
(R)-alpha lipoic acid
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT01261143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261143.